Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party

Bazarbachi, Ali; Boumendil, Ariane; Finel, Hervé; Mohty, Mohamad; Castagna, Luca; Blaise, Didier; Peggs, Karl S.; Afanasyev, Boris; Díez-Martin, José L.; Corradini, Paolo; Michonneau, David; Robinson, Stephen; Gutiérrez-García, Gonzalo; Bonifazi, Francesca; Yakoub‐Agha, Ibrahim; Gülbaş, Zafer; Bloor, Adrian; Delage, Jérémy; Esquirol, Albert; Malladi, Ram; Scheid, Christof; El‐Cheikh, Jean; Ghesquières, Hervé; Montoto, Silvia; Dreger, Peter; Sureda, Anna

doi:10.1002/cncr.31755

Cited by 15 publications

(10 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…CD30 blockade compromises the CD4+ T-cell mediated immune system ( 18 ). A recent report suggested that brentuximab with/without DLI is an effective salvage therapy for relapse of HL after alloHCT irrespective of pretransplant use of brentuximab ( 19 ). We described an HL patient who relapsed after alloHCT and in whom PR was achieved after three cycles of brentuximab and DLI.…”

Section: Discussionmentioning

confidence: 99%

Case Report: Severe COVID-19 Pneumonia in a Patient With Relapsed/Refractory Hodgkin’s Lymphoma

et al. 2021

View full text Add to dashboard Cite

First identified in China in December 2019, coronavirus disease 2019 (COVID-19) has rapidly evolved into a global pandemic. The presence of haematological malignancies are expected to increase the risk of adverse outcomes from this viral infection due to the immunosuppression brought about by the underlying cancer and the effects of therapy. We present a 55-year-old woman diagnosed with relapsed/refractory Hodgkin’s lymphoma (HL) who had been heavily pretreated with multiagent chemotherapy, autologous hematopoietic stem cell transplantation (autoHCT), allogeneic hematopoietic stem cell transplantation (alloHCT) and was complicated with EBV associated posttransplant lymphoproliferative disease (PTLD) and chronic graft-versus-host-disease (GVHD). The patient was recently treated with brentuximab and donor lymphocyte infusion (DLI) for relapse after alloHCT. She suffered from severe COVID-19 pneumonia and eventually succumbed to acute respiratory distress syndrome (ARDS) and multiorgan failure. Of note, this is the first reported case of COVID-19 in a HL patient who was being treated with brentuximab for relapse after alloHCT.

show abstract

Section: Discussionmentioning

confidence: 99%

Case Report: Severe COVID-19 Pneumonia in a Patient With Relapsed/Refractory Hodgkin’s Lymphoma

et al. 2021

View full text Add to dashboard Cite

show abstract

“…At last follow-up, 34% of the original BV cohort were alive and in CR versus 18% in the group that did not receive BV (p = 0.003). The combination of BV with donor lymphocyte infusion was associated with the highest probability of being alive in CR at the time of last follow-up [68].…”

Section: Immunotherapies For Relapse After Allogeneic Hctmentioning

confidence: 92%

“…The probability of being alive and in CR was highest in the group of patients who received BV followed by DLI (40%) compared to 11% in patients who did not receive any, 24% in patients who received DLI only, 21% in patients who received BV only, and 24% in patients who received DLI followed by BV (p = 0.003). In multivariate analysis, the use of DLI was found to significantly improved OS [HR 0.51 (0.32-0.83), p = 0.007] [68]. There are two main studies assessing the use of CPI after allo-HCT.…”

Section: Immunotherapies For Relapse After Allogeneic Hctmentioning

confidence: 99%

Latest advances in the management of classical Hodgkin lymphoma: the era of novel therapies

et al. 2021

Self Cite

View full text Add to dashboard Cite

Hodgkin lymphoma is a highly curable disease. Although most patients achieve complete response following frontline therapy, key unmet clinical needs remain including relapsed/refractory disease, treatment-related morbidity, impaired quality of life and poor outcome in patients older than 60 years. The incorporation of novel therapies, including check point inhibitors and antibody–drug conjugates, into the frontline setting, sequential approaches, and further individualized treatment intensity may address these needs. We summarize the current treatment options for patients with classical Hodgkin lymphoma from frontline therapy to allogeneic hematopoietic stem cell transplantation and describe novel trials in the field.

show abstract

“…Post-transplantation BV may synergize with immune intervention such as DLI to achieve sustained control of HL recurring after allo-HCT. Prospective randomized trials are needed to address this question [69].…”

Section: Haploidentical Stem-cell Transplantationmentioning

confidence: 99%

Stem-Cell Transplantation in Adult Patients with Relapsed/Refractory Hodgkin Lymphoma

Stavrik

Sureda

2021

Transplantology

Self Cite

View full text Add to dashboard Cite

Although the majority of patients with Hodgkin lymphoma (HL) are cured with initial therapy, in 85–90% of early stage and 70–80% of advanced-stage disease cases, relapse remains a major problem. Autologous stem-cell transplantation (auto-HCT) after salvage chemotherapy is currently considered to be the standard of care for patients who relapse after first-line chemotherapy or for whom first-line treatment fails. The curative capacity of auto-HCT has been improving with the introduction of new drug-based salvage strategies and consolidation strategies after auto-HCT. Allogeneic stem-cell transplantation (allo-HCT) represents a reasonable treatment option for young patients who relapse or progress after auto-HCT and have chemosensitive disease at the time of transplantation. Allo-HCT is a valid treatment strategy for patients with relapse/refractory HL (r/r HL) because the results have improved over time, mainly with the safe combination of allo-HCT and new drugs. Bearing in mind that outcomes after haploidentical stem-cell transplantation (haplo-HCT) are comparable with those for matched sibling donors and matched unrelated donors, haplo-HCT is now the preferred alternative donor source for patients with r/r HL without a donor or when there is urgency to find a donor if a matched related donor is not present. The development of new drugs such as anti-CD 30 monoclonal antibodies and checkpoint inhibitors (CPI) for relapsed or refractory HL has demonstrated high response rates and durable remissions, and challenged the role and timing of HCT. The treatment of patients with HL who develop disease recurrence or progression after allo-HCT remains a real challenge and an unmet need.

show abstract

Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party

Cited by 15 publications

References 35 publications

Case Report: Severe COVID-19 Pneumonia in a Patient With Relapsed/Refractory Hodgkin’s Lymphoma

Case Report: Severe COVID-19 Pneumonia in a Patient With Relapsed/Refractory Hodgkin’s Lymphoma

Latest advances in the management of classical Hodgkin lymphoma: the era of novel therapies

Stem-Cell Transplantation in Adult Patients with Relapsed/Refractory Hodgkin Lymphoma

Contact Info

Product

Resources

About